Amarin Corp Plc (AMRN)

[sts66]

IIRC one of the criticisms of STRENGTH was that they enrolled too many patients too fast, so my guess is they may have upped the # of events, not the median time in the trial. I forget exactly when they added the extra year, but some here believe it was because like what R-IT showed, major event curve separation didn't become apparent until patients had been in the trial for almost two years. That's one thing I think of every time someone says "FDA delaying R-IT approval by 3 months will kill thousands" - that's not the case, because V does not have anything close to rapid efficacy for 3 and 5 pt MACE. IMO V may be able to reduce risk of stroke relatively quickly, if Lp-PLA2 is as strong a risk indicator for stroke as it appears to be - my levels dropped -80% after 6 months, and I'd be willing to bet they came down a lot faster than that, we just didn't retest until my next appt.